Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy

Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality, and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have revolutionized clinical cancer care; however, there is little experience with these agents in the management of APTs. Vasc...

Full description

Bibliographic Details
Main Authors:	Lydia S. Lamb, Hao-Wen Sim, Ann I. McCormack
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Endocrinology
Subjects:	aggressive pituitary tumors pituitary carcinoma immunotherapy immune checkpoint inhibitor vascular endothelial growth factor inhibitor biomarker
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2020.576027/full

id	doaj-311244e69a514362a94c61ea3349f3fd
record_format	Article
spelling	doaj-311244e69a514362a94c61ea3349f3fd2020-11-25T04:08:22ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922020-11-011110.3389/fendo.2020.576027576027Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition TherapyLydia S. Lamb0Lydia S. Lamb1Hao-Wen Sim2Hao-Wen Sim3Ann I. McCormack4Ann I. McCormack5Ann I. McCormack6Garvan Institute of Medical Research, Sydney, NSW, AustraliaSt Vincent’s Clinical School, University of New South Wales, Sydney, NSW, AustraliaSt Vincent’s Clinical School, University of New South Wales, Sydney, NSW, AustraliaThe Kinghorn Cancer Centre, Sydney, NSW, AustraliaGarvan Institute of Medical Research, Sydney, NSW, AustraliaSt Vincent’s Clinical School, University of New South Wales, Sydney, NSW, AustraliaDepartment of Endocrinology, St Vincent’s Hospital, Sydney, NSW, AustraliaAggressive pituitary tumors (APTs) are associated with significant morbidity and mortality, and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have revolutionized clinical cancer care; however, there is little experience with these agents in the management of APTs. Vascular endothelial growth factor (VEGF) targeted therapy has reported success in a small number of APT case reports. Here we describe a case of pituitary carcinoma responding to ICI therapy and subsequently VEGF inhibition. We discuss the possible mechanisms and experience with ICI therapy and VEGF inhibitors in the management of APTs, biomarkers that may predict response, and the potential role of combination therapies including ICIs and temozolomide.https://www.frontiersin.org/articles/10.3389/fendo.2020.576027/fullaggressive pituitary tumorspituitary carcinomaimmunotherapyimmune checkpoint inhibitorvascular endothelial growth factor inhibitorbiomarker
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Lydia S. Lamb Lydia S. Lamb Hao-Wen Sim Hao-Wen Sim Ann I. McCormack Ann I. McCormack Ann I. McCormack
spellingShingle	Lydia S. Lamb Lydia S. Lamb Hao-Wen Sim Hao-Wen Sim Ann I. McCormack Ann I. McCormack Ann I. McCormack Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy Frontiers in Endocrinology aggressive pituitary tumors pituitary carcinoma immunotherapy immune checkpoint inhibitor vascular endothelial growth factor inhibitor biomarker
author_facet	Lydia S. Lamb Lydia S. Lamb Hao-Wen Sim Hao-Wen Sim Ann I. McCormack Ann I. McCormack Ann I. McCormack
author_sort	Lydia S. Lamb
title	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
title_short	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
title_full	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
title_fullStr	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
title_full_unstemmed	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy
title_sort	case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy
publisher	Frontiers Media S.A.
series	Frontiers in Endocrinology
issn	1664-2392
publishDate	2020-11-01
description	Aggressive pituitary tumors (APTs) are associated with significant morbidity and mortality, and effective treatment options are limited. Immune checkpoint inhibitors (ICIs) have revolutionized clinical cancer care; however, there is little experience with these agents in the management of APTs. Vascular endothelial growth factor (VEGF) targeted therapy has reported success in a small number of APT case reports. Here we describe a case of pituitary carcinoma responding to ICI therapy and subsequently VEGF inhibition. We discuss the possible mechanisms and experience with ICI therapy and VEGF inhibitors in the management of APTs, biomarkers that may predict response, and the potential role of combination therapies including ICIs and temozolomide.
topic	aggressive pituitary tumors pituitary carcinoma immunotherapy immune checkpoint inhibitor vascular endothelial growth factor inhibitor biomarker
url	https://www.frontiersin.org/articles/10.3389/fendo.2020.576027/full
work_keys_str_mv	AT lydiaslamb casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT lydiaslamb casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT haowensim casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT haowensim casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT annimccormack casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT annimccormack casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy AT annimccormack casereportacaseofpituitarycarcinomatreatedwithsequentialdualimmunotherapyandvascularendothelialgrowthfactorinhibitiontherapy
_version_	1724426122349772800

Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy

Similar Items